Work

All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis

Year: 2025

Type: article

Abstract: Background Limited literature exists on the mortality burden of generalized pustular psoriasis (GPP) in the US. Objective To compare all-cause mortality among patients with GPP with matched populations of patients with plaque psoriasis (PsO) and the general population in the US. Methods An observational study was conducted using US claims data collected between January 1, 2016 and December 31, 2019. All-cause mortality was evaluated at 365 days post-index and at maximum follow-up in the following cohorts: GPP-only , Plaque-PsO-only , GPP + PsO , All-GPP , and general population . Propensity score matching was used to balance covariates between cohorts. The index date was the first medical claim for GPP (ICD-10 code L40.1) or PsO (L40.0), and a randomly selected date per year for individuals in the general population cohort. Results 1246 patients were included in GPP-only , 1384 in GPP + PsO , 2630 in All-GPP and 127,540 in plaque-PsO-only . 19,641,441 individuals were included in general population . The maximum follow-up ranged from 36.14 to 41.28 months (3.01-3.44 years). At 365-day follow-up, mortality risk was significantly higher in the All-GPP vs the general population (hazard ratio [HR] 4.93, 95% confidence interval [CI] 2.24-10.88) and plaque-PsO-only (HR 2.31, 95% CI 1.32-4.04) cohorts. At maximum follow-up, the mortality risk for the All-GPP cohort was four times higher than the general population (HR 3.98, 95% CI 2.92-5.43) and 1.5 times higher than the plaque-PsO-only (HR 1.49, 95% CI 1.20-1.85) cohorts. Conclusion Patients with GPP exhibited an elevated mortality risk in comparison to the matched plaque-PsO and general population cohorts.

Source: Journal of Psoriasis and Psoriatic Arthritis

DOI: 10.1177/24755303251344155

Authors: Alice B. Gottlieb, Hannah Crooke Kwiatkowski, Juan Semeco, Bhargav Lakshminarasimhan, Bruce Strober, Mark Lebwohl

Institutions: Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim (Germany), Yale University

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Boehringer Ingelheim